Skip to main content
Figure 3 | BMC Clinical Pharmacology

Figure 3

From: In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes

Figure 3

Inactivation of the recombinant and human PON1, and PON1-HDL complexes by glutathione. Data represents mean ± SD of at least 3 independent experiments. A. Recombinant and human PON1, and the corresponding HDL complexes, were incubated with increasing concentrations of GSSG at 37°C. Residual PON1 activity was determined after 40 min of incubation, and plotted as percentage of the initial activity. B. Recombinant and human PON1, and the corresponding HDL complexes, were incubated with various GSH/GSSG ratios (the ratios are expressed as the ratio of glutathione equivalents, i.e., the ratio of GSH to 2xGSSG) whilst keeping the total glutathione concentration at 10 mM. Residual PON1 activity was determined after 40 min of incubation, and plotted as percentage of the initial activity.

Back to article page